Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

02 May 2003

Treatment of INS-1 pancreatic b-cells with poly(ADP-ribose) polymerase (PARP) inhibitors attenuates glucose-induced changes in insulin and lipogenic gene expression

L. Olson, K. Linning, D. Jump, D. Ye

Med Sci Monit 2003; 9(1): 51- :: ID: 15114

Abstract

Chronic hyperglycemia can alter pancreatic b-cell phenotype by decreasing expression of b-cell specific genes including insulin and GLUT2, while increasing expression of metabolic genes normally not abundantly expressed such as l-pyruvate kinase (l-PK), fatty acid synthase (FAS), acetyl-CoA carboxylase, and lactate dehydrogenase. Treatment of INS-1 pancreatic b-cells with high glucose (16.7 mM) for 48 hrs markedly suppressed insulin promoter activity [1] and induced l-PK promoter activity [1,2]. High glucose also elevated intracellular NAD levels 2-fold compared to control. PARP, an enzyme that uses NAD to poly(ADP-ribosy)late nuclear proteins [3], has been suggested to be involved in ß-cell cytotoxicity, regeneration and differentiation [2,4], and adipocyte differentiation [5]. Thus, we examined the ability of PARP inhibitors – nicotinamide (NAM), 3-aminobenzamide (3-AB), and PD128763 (PD) – to attenuate glucose-mediated changes in insulin and lipogenic gene expression and promoter activities in INS-1 cells. Incubation of INS-1 cells in high glucose for 48 hrs suppressed in suppressed insulin mRNA level >80% and induced l-PK, FAS, and SREBP-1c mRNA levels 4.4-, 12.6-, and 2.7-fold, respectively. Treatment with high glucose concentrations also repressed insulin (–327/+30) promoter activity >80%, and induced l-PK (–4.3 kb/+12) and FAS (–2.4 kb/+16) promoter activity 24- and 21-fold, respectively. Treatment of cells with high glucose plus 10 mM NAM, 10 mM 3-AB, or 500 KM PD, increased insulin mRNA levels and promoter activity 3.4- and 10-fold, respectively. PARP inhibitors also attenuated glucose-mediated induction of l-PK, FAS, and SREBP-1c mRNA levels by 55%, 69%, and 45%, respectively. Moreover, PARP inhibitors attenuated the ability of high glucose to activate l-PK and FAS promoters by 51% and 61%, respectively. These results indicate that PARP inhibitors can attenuate adverse changes in gene expression that occur when b-cells are exposed to elevated glucose concentrations.References: 1.Olson LK, Qian J, Poitout V: Mol Endocrinol, 1998; 12(2): 207-219 2.Newburg E, Qian J, Towle HC, Olson LK: Mol Cell Biochem, 2000; 210: 13-21 3.Virag L, Szabo C: Pharmacol Rev, 2002; 54(3): 375-429 4.Okamoto H, Takasawa S: Diabetes, 2002; 51(suppl. 3): S462-S473 5.Smulson ME, Kang VH, Ntambi JM et al: J Biol Chem, 1995; 270(1): 119-127

Keywords: PARP inhibitors, b-cell phenotype, islet of langerhans, Glucose, insulin gene, lipogenic genes

0 Comments

Editorial

01 December 2022 : Editorial  

Editorial: The World Health Organization (WHO) Fungal Priority Pathogens List in Response to Emerging Fungal Pathogens During the COVID-19 Pandemic

Dinah V. Parums
Science Editor, Medical Science Monitor, International Scientific Information, Inc., Melville, NY, USA

DOI: 10.12659/MSM.939088

Med Sci Monit 2022; 28:e939088

SARS-CoV-2/COVID-19

29 November 2022 : Clinical Research  

Retrospective Study to Identify Risk Factors for Severe Disease and Mortality Using the Modified Early Warn...

Med Sci Monit In Press; DOI: 10.12659/MSM.938647  

24 November 2022 : Clinical Research  

A Prospective Questionnaire-Based Study to Evaluate Factors Affecting the Decision to Receive COVID-19 Vacc...

Med Sci Monit In Press; DOI: 10.12659/MSM.938665  

01 November 2022 : Clinical Research  

Questionnaire-Based Study of 81 Patients in Poland to Evaluate the Course of Inflammatory Bowel Disease and...

Med Sci Monit 2022; 28:e938243

In Press

02 Dec 2022 : Clinical Research  

Value of Early Laparoscopic Exploration for Primary Infertile Patients with Patent Fallopian Tubes Complica...

Med Sci Monit In Press; DOI: 10.12659/MSM.938637  

30 Nov 2022 : Clinical Research  

Retrospective Evaluation of Hematological and Clinical Factors Associated with 30-Day Mortality in 170 Pati...

Med Sci Monit In Press; DOI: 10.12659/MSM.938674  

29 Nov 2022 : Clinical Research  

Retrospective Study to Identify Risk Factors for Severe Disease and Mortality Using the Modified Early Warn...

Med Sci Monit In Press; DOI: 10.12659/MSM.938647  

28 Nov 2022 : Review article  

A Review of the Roles of Apelin and ELABELA Peptide Ligands in Cardiovascular Disease, Including Heart Fail...

Med Sci Monit In Press; DOI: 10.12659/MSM.938112  

Most Viewed Current Articles

13 Nov 2021 : Clinical Research  

Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...

DOI :10.12659/MSM.932788

Med Sci Monit 2021; 27:e932788

30 Dec 2021 : Clinical Research  

Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...

DOI :10.12659/MSM.935379

Med Sci Monit 2021; 27:e935379

01 Nov 2020 : Review article  

Long-Term Respiratory and Neurological Sequelae of COVID-19

DOI :10.12659/MSM.928996

Med Sci Monit 2020; 26:e928996

08 Mar 2022 : Review article  

A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...

DOI :10.12659/MSM.936292

Med Sci Monit 2022; 28:e936292

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750